"id","rationale","instanceType","uuid:ID","versionIdentifier"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","1ee30bc1-1564-4ada-aa2b-763a72861475","2"
